e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Experimental pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Involvement of cytoskeletal protein paxillin in the pathogenesis of pulmonary hypertension
C. Veith, W. Seeger, N. Weissmann, G. Kwapiszewska (Giessen, Germany)
Source:
Annual Congress 2011 - Experimental pulmonary hypertension
Session:
Experimental pulmonary hypertension
Session type:
Poster Discussion
Number:
3344
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Veith, W. Seeger, N. Weissmann, G. Kwapiszewska (Giessen, Germany). Involvement of cytoskeletal protein paxillin in the pathogenesis of pulmonary hypertension. Eur Respir J 2011; 38: Suppl. 55, 3344
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1426-1433
Year: 2015
Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension
Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020
Year: 2021
PP208 – SRC family kinases modulate molecular pathways associated with mitochondrial dysfunction in idiopathic pulmonary fibrosis
Source: ERS Lung Science Conference 2021
Year: 2021
Role of c-Abelson in the loss of genome integrity in endothelial cells in pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Epigenetic-like regulation of signalling proteins in chronic obstructive pulmonary disease
Source: International Congress 2019 – Effects of environmental exposures in lung pathology and the underlying mechanisms
Year: 2019
NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Syk expression and function in the pulmonary vasculature
Source: International Congress 2018 – New kids on the block: novel molecular pathways and therapeutic targets in chronic lung diseases
Year: 2018
LATE-BREAKING ABSTRACT: TNFalpha mediates ectodomain shedding of BMPR-II: A potential role in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed
Source: Eur Respir J 2013; 41: 3-4
Year: 2013
CFTR involvement in the pathogenesis of pulmonary arterial hypertension
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Increased activity of Lyn tyrosine kinase causes multiple chronic obstructive pulmonary disease-like changes in mouse
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Contribution of angiopoietin/Tie2 pathway to pulmonary artery smooth muscle hyperplasia in idiopathic pulmonary hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Dysregulated bone morphogenetic protein signaling in pulmonary arterial hypertension
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Vascular remodeling in chronic thromboembolic pulmonary hypertension: Involvement of dedifferentiated smooth muscle cells and C-reactive protein
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010
Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension
Source: Eur Respir J, 58 (2) 2101645; 10.1183/13993003.01645-2021
Year: 2021
RhoA signalling influences cyclin D1 expression and associated fibroblast turnover: implications for idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling
Year: 2006
Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension
Source: Eur Respir J 2009; 34: 1100-1110
Year: 2009
The dysregulation of E-cadherin contributes to pulmonary emphysema
Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia
Year: 2017
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 147s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept